Bioclinica acquires clinical trial AI firm

By The Science Advisory Board staff writers

January 6, 2021 -- Clinical trial management services firm Bioclinica has acquired Saliency, the developer of an artificial intelligence (AI)-based software that speeds medical image interpretation to help support pharmaceutical and medical device clients in clinical trials.

Saliency's platform uses proprietary algorithms to build and train AI models quickly from a small number of deidentified images. The models can be used to screen, redact, or interpret medical images to support numerous therapeutic areas.

The AI capability will be embedded into Bioclinica's current and future imaging products and services for research sponsors and clinical research organizations.


Copyright © 2021 scienceboard.net
 


Email Address:

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.